Silo Pharma Secures Patent that May be Used for Psychedelics Delivery Technology
August 17th, 2021
App, Psychedelics, Top Story
Silo Pharma’s notice of allowance paves the way toward clinical trials for its psychedelics delivery platform using homing peptides.
Silo Pharma Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the therapeutic potential of psychedelics, recently announced that the U.S. Patent Office issued a notice of allowance for its technology/method patent covering an isolated homing peptide and how it can help deliver drugs to the central nervous system (CNS).
“We are pleased to have been granted this patent by the United States Patent and Trademark Office for our novel homing peptide,” said CEO Eric Weisblum in a press release announcing the USPTO’s decision. “We will continue to expand our intellectual property portfolio related to markets where our novel therapeutics can be applied.”
After filing a provisional patent application, an examiner from the USPTO determines if an invention qualifies for a patent. Once the examiner decides to grant the patent, they issue a notice of allowance, which means that the patent is valid after paying registration fees.
The company’s efforts to secure patents are the cornerstone of its strategy to develop and license therapeutics. Unlike competitors administering generic psychedelics, the company’s patented technology could improve safety and efficacy while guaranteeing market exclusivity.
Bringing Products to Market
Silo Pharma initially entered into an exclusive agreement with the University of Maryland-Baltimore to license its patented homing peptides targeting rheumatoid arthritis (RA)—a market that’s projected to reach nearly $63 billion by 2027.
Management believes that the same technologies could also address a much larger market for central nervous system therapeutics. According to Global Industry Analysts, the global CNS therapeutics market could reach more than $132 billion by 2024.
The homing peptides work by helping conventional therapeutics better target diseased tissue. Through better targeting, the company could enhance efficacy and minimize toxicity by potentially reducing the amount of active ingredients needed to achieve the same outcome and opening the door to safely delivering more active ingredients.
The company believes that the same homing peptide approach could improve the safety and efficacy of psychedelic treatments. In August 2020, the company also filed three provisional patent applications covering the central nervous system delivery of psilocybin and NSAIDs, as well as a fourth provisional patent covering the use of psilocybin for cancer treatment.
Visit the company’s website to learn more about its pipeline and IP portfolio.
Presently, the company is working with researchers to build out these technologies and pave the way for clinical trials. The goal is to target FDA designations that would expedite clinical trials while extending exclusivity periods, creating more value than conventional drugs.
Looking to the Future
Silo Pharma Inc. (OTCQB: SILO) has numerous upcoming catalysts that investors should watch over the coming months. For example, the company has several ongoing preclinical and clinical trials, such as its Phase 2B study of psychedelics for treating Parkinson’s disease.
As it secures patents, the company can license these therapeutics to big pharma companies that can take them through Phase II and III clinical trials. Management’s long-term goal is to maintain a capital-efficient strategy that builds long-term, high-margin royalty income.
The company also owns one million shares of DatChat, Inc. (NASDAQ: DATS)—a privacy-focused communication company that recently went public on the NASDAQ. With a share price of around $3.70, the company’s position is worth around $3.6 million, subject to restrictions and other conditions on their holdings.
To learn more, visit the company’s website or download their investor presentation.
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.